Effect of Mild and Moderate Hepatic Impairment (Defined by Child–Pugh Classification and National Cancer Institute Organ Dysfunction Working Group Criteria) on Pexidartinib Pharmacokinetics

Pexidartinib is a novel oral small‐molecule tyrosine kinase inhibitor targeting the colony‐stimulating factor 1 receptor. Pexidartinib undergoes extensive hepatic metabolism via multiple cytochrome P450 and uridine 5'‐diphospho‐glucuronosyl transferase enzymes, with ZAAD‐1006a as the only major...

Descripción completa

Detalles Bibliográficos
Autores principales: Zahir, Hamim, Greenberg, Jonathan, Hsu, Ching, Marbury, Thomas C., Lasseter, Kenneth C., Xu, Li‐An, Tap, William D., Healey, John H., Stacchiotti, Silvia, LaCreta, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Special Populations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288539/
https://www.ncbi.nlm.nih.gov/pubmed/35247274
http://dx.doi.org/10.1002/jcph.2042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288539/
https://www.ncbi.nlm.nih.gov/pubmed/35247274
http://dx.doi.org/10.1002/jcph.2042

Ejemplares similares